Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.
作者信息
Cate Vincent Ten, Lensing Anthonie W A, Weitz Jeffrey I, Beyer-Westendorf Jan, Wells Philip S, Mismetti Patrick, Prandoni Paolo, Cohen Alexander T, Davidson Bruce L, Prins Martin H
机构信息
Department of Epidemiology, Maastricht University Medical Center, Maastricht, the Netherlands
Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy, and Bayer AG, Wuppertal, Germany.
出版信息
Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7.
Abstract
摘要
相似文献
1
Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.静脉血栓栓塞症的延长抗凝治疗：一项基于临床病例的平衡、析因设计研究
Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7.
2
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.CATCH 研究中癌症患者静脉血栓栓塞治疗的临床相关出血。
J Thromb Haemost. 2018 Jun;16(6):1069-1077. doi: 10.1111/jth.14007. Epub 2018 Apr 17.
3
Duration of anticoagulant therapy for patients with venous thromboembolism.静脉血栓栓塞症患者的抗凝治疗持续时间。
Thromb Res. 2008;123 Suppl 1:S62-4. doi: 10.1016/j.thromres.2008.08.019. Epub 2008 Sep 26.
4
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.达比加群或华法林治疗急性静脉血栓栓塞症及汇总分析。
Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16.
5
Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.接受华法林治疗的癌症患者静脉血栓栓塞的复发情况。
Clin Appl Thromb Hemost. 2015 Oct;21(7):632-8. doi: 10.1177/1076029615579099. Epub 2015 Apr 7.
6
Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.癌症相关静脉血栓栓塞症抗凝治疗时抗凝药物选择对住院出血风险的影响。
J Thromb Haemost. 2018 Dec;16(12):2403-2412. doi: 10.1111/jth.14303. Epub 2018 Oct 24.
7
Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.利伐沙班与华法林在极度肥胖和高体重人群中的卒中预防和静脉血栓栓塞症治疗中的比较。
Ann Pharmacother. 2020 Apr;54(4):344-350. doi: 10.1177/1060028019886092. Epub 2019 Oct 31.
8
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.阿哌沙班与华法林治疗静脉血栓栓塞症患者的疗效和安全性比较。
Am J Health Syst Pharm. 2020 Jan 24;77(3):188-195. doi: 10.1093/ajhp/zxz307.
9
Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.直接口服抗凝剂与华法林在肥胖合并静脉血栓栓塞症患者中的安全性和有效性：一项回顾性分析。
Tex Heart Inst J. 2024 May 15;51(1). doi: 10.14503/THIJ-23-8260.
10
Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes.华法林治疗静脉血栓栓塞症患者：使用模式和临床结局的预测因素。
Adv Ther. 2010 Sep;27(9):623-33. doi: 10.1007/s12325-010-0056-z. Epub 2010 Jul 30.
引用本文的文献
1
Impact of the VTE-PREDICT calculator on clinicians' decision making in fictional patients with venous thromboembolism: a randomized controlled trial.VTE-PREDICT计算器对虚构的静脉血栓栓塞症患者中临床医生决策的影响：一项随机对照试验
Res Pract Thromb Haemost. 2024 Sep 11;8(7):102569. doi: 10.1016/j.rpth.2024.102569. eCollection 2024 Oct.
2
Residual Venous Obstruction as an Indicator of Clinical Outcomes following Deep Vein Thrombosis: A Management Study.静脉血栓栓塞症后残余静脉阻塞作为临床结局的指标：一项管理研究。
Thromb Haemost. 2023 Aug;123(8):763-772. doi: 10.1055/a-2059-4737. Epub 2023 Mar 21.
本文引用的文献
1
Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries.静脉血栓栓塞症的二级预防决策：对13个国家临床实践的访谈
Res Pract Thromb Haemost. 2017 Jun 20;1(1):41-48. doi: 10.1002/rth2.12014. eCollection 2017 Jul.
2
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.初发性无诱因静脉血栓栓塞症患者初始口服抗凝治疗后复发性静脉血栓栓塞症的二级预防
Cochrane Database Syst Rev. 2017 Dec 15;12(12):CD011088. doi: 10.1002/14651858.CD011088.pub2.
3
Determinants of treatment duration in the prevention of recurrent venous thromboembolism: a protocol for a balanced vignette experiment.预防复发性静脉血栓栓塞症治疗持续时间的决定因素：一项平衡案例实验方案
BMJ Open. 2017 May 10;7(5):e015231. doi: 10.1136/bmjopen-2016-015231.
4
Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?对于静脉血栓栓塞症患者，遵循美国胸科医师学会推荐的抗凝治疗持续时间是否与不同结局相关？
Clin Appl Thromb Hemost. 2017 Sep;23(6):532-541. doi: 10.1177/1076029616680475. Epub 2016 Nov 30.
5
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.抗栓治疗 VTE 疾病：CHEST 指南和专家小组报告。
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
6
Guidance for the prevention and treatment of cancer-associated venous thromboembolism.癌症相关静脉血栓栓塞的防治指南。
J Thromb Thrombolysis. 2016 Jan;41(1):81-91. doi: 10.1007/s11239-015-1313-4.
7
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.利伐沙班与依诺肝素/维生素K拮抗剂治疗对静脉血栓栓塞合并肾功能损害患者的疗效比较
Thromb J. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014.
8
Recurrent venous thromboembolism: what is the risk and how to prevent it.复发性静脉血栓栓塞：风险是什么以及如何预防
Scientifica (Cairo). 2012;2012:391734. doi: 10.6064/2012/391734. Epub 2012 Sep 17.
9
Venous thromboembolism: advances and controversies. Preface.静脉血栓栓塞症：进展与争议。前言。
Best Pract Res Clin Haematol. 2012 Sep;25(3):233. doi: 10.1016/j.beha.2012.07.009. Epub 2012 Aug 14.
10
Isolated distal deep vein thrombosis: what we know and what we are doing.孤立性远端深静脉血栓：我们的所知与所为。
J Thromb Haemost. 2012 Jan;10(1):11-9. doi: 10.1111/j.1538-7836.2011.04564.x.
Zotero 插件